There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Emergent Biosolutions (EBS – Research Report) and HeartBeam (BEAT – Research Report) with bullish sentiments.
Emergent Biosolutions (EBS)
Benchmark Co. analyst Robert Wasserman reiterated a Buy rating on Emergent Biosolutions today and set a price target of $22.00. The company’s shares closed last Friday at $8.29, close to its 52-week low of $7.74.
According to TipRanks.com, Wasserman is a 1-star analyst with an average return of
Currently, the analyst consensus on Emergent Biosolutions is a Hold with an average price target of $15.33.
See the top stocks recommended by analysts >>
HeartBeam (BEAT)
Benchmark Co. analyst Bill Sutherland reiterated a Buy rating on HeartBeam today and set a price target of $8.00. The company’s shares closed last Friday at $2.18.
According to TipRanks.com, Sutherland has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for HeartBeam with a $6.78 average price target, representing a 208.2% upside. In a report released today, Alliance Global Partners also maintained a Buy rating on the stock with a $5.55 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EBS:
- Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
- Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
- EBS Earnings this Week: How Will it Perform?
- Emergent BioSolutions falls -4.1%
- Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
